Jim Cramer's Mad Dash: ISRG STZ

NEW YORK (TheStreet) -- TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, called Intuitive Surgical's (ISRG) recent earnings results a "severe disappointment" during CNBC's "Cramer's Mad Dash" segment Wednesday.

However, analysts continue to stand behind the name, Cramer said. He suggested investors listen to TheStreet's Herb Greenberg's view on the stock, which have been relatively accurate. 

Cramer added that product demand seems to be the main problem for Intuitive Surgical, evident by the 24% year-over-year decline in sales. "Stay away from ISRG," he told investors because perhaps "demand has peaked" for its medical devices. 

Turning to Constellation Brands (STZ), Cramer was much more bullish. The company beat on bottom-line estimates and provided strong fiscal year guidance. 

He said the company's 2013 acquisition of Grupo Modelo -- which includes Crown Imports LLC, the maker of Corona -- has been a real difference-maker for the company. 

Because of the deal, Cramer said shares of STZ are still cheap, despite the stock appreciating 69% in the past 12 months thanks to earnings results and guidance that continue to grow.


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

These 5 Tech Giants Still Aren't That Expensive

These 5 Tech Giants Still Aren't That Expensive

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others